These benefits may, at least in part, be mediated through modulation of key cellular pathways such as the aryl hydrocarbon receptor (AhR) and G protein-coupled receptor 35 (GPR35), which are involved in controlling inflammation and may contribute to tumor prevention, particularly in genetically predisposed individuals. The gene discussed is GPR35; the disease is neoplasm.